A taste of its own medicine: Singapore banks on pharmaceuticals to boost ailing exports

We're sorry, tech producers.

Singapore’s increased capacity to produce pharmaceutical drugs has boosted exports to the US and Europe, despite Singapore’s lackluster non-oil domestic exports situation.

Moody’s Analytics says that the global shift away from PCs is hurting Singapore’s tech producers, as are more cost-effective and larger-scale producers elsewhere in the region.

Singapore’s manufactured exports continue to diversify away from electronics as exports of semiconductors, disk drives, and other PC components are falling at double-digit year-on-year rates, and this is likely to continue, adds Moody’s Analytics.

Meanwhile, DBS thinks that the manufacturing sector is also weighed down by structural challenges. According to them, domestic restructuring has resulted in a labour crunch, which is crimping export competitiveness and affecting the performance of exports and manufacturing.

Reaching the people who run Asia's businesses is harder than it used to be.

Inboxes are crowded. Attention is short. The executives you most want to reach — the founders, CFOs, and operators who actually move budgets — are the hardest to find through the usual channels. If you're building a company, a category, or a reputation, you already know this.

We've spent twenty years building the room they read. Singapore Business Review is where senior decision makers in Singapore and across Southeast Asia come for business coverage they can't get elsewhere — in print, online, and in person at the summits and roundtables we host across seven markets.

If you have something these readers should know about — a point of view worth publishing, a product worth their attention, an event worth their time — we'd like to hear what you're trying to do.

Book a meeting

| Or download the media kit (PDF)

240,000 senior readers quarterly in print Top 1,700 Singapore companies reached

7 markets across Southeast Asia